AKT1 and myotonic dystrophy type 1: Although pioglitazone has been observed to improve insulin resistance and reduce inflammatory markers, whether it acts by directly correcting the core pathological mechanisms of DM1 (e.g., correcting splicing abnormalities) or through other signaling pathways (such as the AKT pathway) requires further in-depth molecular research to clarify (119).